Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema
- 281 Downloads
Hereditary angioedema (HAE) is a rare disorder characterized by highly variable, acute attacks of swelling at various anatomical locations. Clinical measures do not adequately assess the diversity of symptoms characteristic of an attack. Two disease-specific, patient-reported outcome measures were developed to comprehensively capture symptom severity and change: the Treatment Outcome Score (TOS) and the Mean Symptom Complex Severity (MSCS) score.
This study comprised a secondary analysis of pooled data from a randomized controlled trial to evaluate the psychometric properties, including reliability and validity, and minimally important difference (MID) of the TOS and MSCS score.
HAE patients (n = 73) had a mean age of 33 years, and 60% were female. Test–retest evaluation demonstrated moderate to substantial agreement (ICCs = 0.53 for TOS; 0.62 for MSCS score). The TOS and change in MSCS score were moderately to highly correlated with a Global Improvement Measure at 4 h (TOS: r = 0.90; MSCS: r = −0.59). Anchor- and distribution-based analyses suggested that conservative estimates for MID are 30 points for TOS and −0.30 points for 4-h change in MSCS score.
The psychometric tests performed here provide evidence of the reliability and validity of the TOS and MSCS for evaluating symptom severity and change in HAE patients. The TOS and MSCS score provide an example of measurement methodology that may be used to precisely capture symptom severity and change in a disease characterized by acute attacks.
KeywordsHereditary angioedema Psychometric validation Patient-reported outcome
The authors thank Leslie E. Stolz, PhD (Dyax Corp.), and Mr. Fritz Hamme, BA (UBC) for assistance with the drafting of this manuscript.
Conflict of interest
Funding for this manuscript was provided by Dyax Corp. All data listings are available upon request. EDEMA3® and EDEMA4® are registered service marks of Dyax.
- 10.Hays, R., & Revicki, D. A. (2005). Reliability and validity (including responsiveness). In R. Hays & D. A. Revicki (Eds.), Assessing quality of life in clinical trials (pp. 25–39). New York, NY: Oxford University Press.Google Scholar
- 13.Vernon, M. K., Rentz, A., White, M., & Schmalbach, T. (2007). Content validity and usability of the treatment outcome score and mean complex severity score: New electronic pros to assess symptom severity and improvement in hereditary angioedema. In 14th Annual Conference of the International Society for Quality of Life Research, Toronto, Ontario, Canada.Google Scholar
- 14.White, M., Vernon, M. K., Rentz, A., Beck, T. R., & Roberts, J. (2007). Development of a Patient-Reported Outcome (PRO) Measure to Assess Symptom Severity and Change in Hereditary Angioedema (HAE). The American College of Allergy, Asthma, & Immunology Annual Scientific Meeting, Dallas, TX.Google Scholar
- 15.Vernon, M. K., Rentz, A. M., White, M. V., & Grienenberger, A. (2008). Validation of a Patient-Reported Outcome Measure to Assess Response to Treatment in Hereditary Angioedema. American College of Asthma, Allergy, & Immunology, Seattle, WA.Google Scholar
- 16.Schneider, L., Lumry, W., Vegh, A., Williams, A. H., & Schmalbach, T. (2007). Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor. The Journal of Allergy and Clinical Immunology, 120(2), 416–422.PubMedCrossRefGoogle Scholar
- 24.Streiner, D. L., & Norman, G. R. (2003). Health measurement scales. Oxford: Oxford University Press.Google Scholar
- 27.Cohen, J. (1988). Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Erlbaum.Google Scholar
- 28.Sloan, J. A., Symonds, T., Vargas-Chanes, D., & Friedly, B. (2003). Practical guidelines for assessing the clinical significance of heath related quality of life changes within clinical trials. Drug Information Journal, 37, 23–31.Google Scholar